

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qyuns Therapeutics Co., Ltd.**  
**江蘇荃信生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE**

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of an update on the latest business developments of the Company.

The board of directors of the Company (the “**Board**”) is of the view that the current share price of the Company significantly undervalues the Company’s worth. With the full confidence in the future development prospects of the Company and high recognition of its intrinsic value, and with a view to continuously reinforcing market confidence in the Company and enhancing the investment value of the Company, pursuant to the share repurchase mandate granted to the directors of the Company (the “**Directors**”), approved by the shareholders of the Company at the annual general meeting held on June 20, 2025, the Company had repurchased a total of 2,487,800 ordinary shares on The Stock Exchange of Hong Kong Limited from November 6, 2025 to the date of this announcement as treasury shares. The shares repurchased represent approximately 1.10% of the existing total number of issued shares of the Company as at the date of this announcement. As at the date of this announcement, the aggregate amount involved in repurchases is approximately HK\$50.75 million (excluding commission and other expenses).

**Shareholders and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to market conditions and will be at the absolute discretion of the Board and/or its authorised person(s). There is no assurance of the timing, quantity or price of any repurchases or whether the Company will make any share repurchase at all. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**

*Chairman of the Board and Executive Director*

Hong Kong, February 5, 2026

*As of the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.*